Subscribe
monticello / Shutterstock.com
30 July 2024NewsAmericasMarisa Woutersen

Sanofi subsidiary sues Sarepta over gene therapy

Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sarepta to tap into CRISPR treatment potential
3 November 2017   Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).
Americas
Sarepta and Biomarin resolve patent dispute with $35m licence
20 July 2017   Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Sarepta to tap into CRISPR treatment potential
3 November 2017   Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).
Americas
Sarepta and Biomarin resolve patent dispute with $35m licence
20 July 2017   Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

More on this story

Americas
Sarepta to tap into CRISPR treatment potential
3 November 2017   Biopharmaceutical company Sarepta Therapeutics is exploring the potential of CRISPR/Cas9 gene editing technology to treat Duchenne muscular dystrophy (DMD).
Americas
Sarepta and Biomarin resolve patent dispute with $35m licence
20 July 2017   Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

More features

UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Bristol Myers Squibb leader named INTA 2025 president
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks